Sign in to view content

2026 First-Place Poster Winner: Evaluating Sleep Disruption as a Modifiable Risk Factor for Central Serous Chorioretinopathy in a National Cohort of Over 5000 Patients

Christina Y Weng, MD, MBA, FASRS

Video
Published 2026

Related

Imaging, Digital, Angiography Symposium 2
Annual Meeting Talks
2020
Short-term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP-CSC): A Placebo-Controlled Clinical Trial
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2018
Obstructive Sleep Apnea and Its Treatment Alter Choroidal Thickness in Patients With Central Serous Chorioretinopathy
Carolyn K Pan, MD
Annual Meeting Talks
2020

Category: Choroidal Diseases- Central Serous Retinopathy

Central Serous Chorioretinopathy

See more